Cooper Companies (COO)

• Market cap: $16.3B
• 1 day: -0.68%
• 5 days: 0.33%
• 1 month: -3.18%
• 3 months: -16.75%
• 6 months: -22.37%
• Year to date: -9.92%
• 1 year: -8.30%
• 5 years: 13.94%
• 10 years: 83.45%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.

Employees: 16,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

69% more call options, than puts

Call options by funds: $14.5M | Put options by funds: $8.6M

36% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 70

3.18% more ownership

Funds ownership: 95.03% [Q3] → 98.2% (+3.18%) [Q4]

3% more funds holding

Funds holding: 649 [Q3] → 667 (+18) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 235 | Existing positions reduced: 249

14% less capital invested

Capital invested by funds: $20.8B [Q3] → $18B (-$2.84B) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $105 29% upside
• Avg. target: $109 34% upside
• High target: $115 41% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Stifel Jonathan Block 10% 1-year accuracy 2 / 20 met price target	29% upside $105	Buy Maintained	7 Mar 2025
JP Morgan Robbie Marcus 41% 1-year accuracy 7 / 17 met price target	35% upside $110	Overweight Maintained	7 Mar 2025
Piper Sandler Jason Bednar 32% 1-year accuracy 12 / 38 met price target	41% upside $115	Overweight Reiterated	7 Mar 2025
Citigroup Joanne Wuensch 45% 1-year accuracy 18 / 40 met price target	35% upside $110	Buy Maintained	7 Mar 2025
Baird Jeff Johnson 37% 1-year accuracy 10 / 27 met price target	31% upside $107	Outperform Maintained	7 Mar 2025